Abstract
Splice-switching therapy with splice-switching oligonucleotides (SSOs) has recently proven to be a clinically applicable strategy for the treatment of several mis-splice disorders. Despite this, wider application of SSOs is severely limited by the inherently poor bioavailability of SSO-based therapeutic compounds. Cell-penetrating peptides (CPPs) are a class of drug delivery systems (DDSs) that have recently gained considerable attention for improving the uptake of various oligonucleotide (ON)-based compounds, including SSOs. One strategy that has been successfully applied to develop effective CPP vectors is the introduction of various lipid modifications into the peptide. Here, we repurpose hydrocarbon-modified amino acids used in peptide stapling for the orthogonal introduction of hydrophobic modifications into the CPP structure during peptide synthesis. Our data show that α,α-disubstituted alkenyl-alanines can be successfully utilized to introduce hydrophobic modifications into CPPs to improve their ability to formulate SSOs into nanoparticles (NPs), and to mediate high delivery efficacy and tolerability both in vitro and in vivo. Conclusively, our results offer a new flexible approach for the sequence-specific introduction of hydrophobicity into the structure of CPPs and for improving their delivery properties.
Highlights
Splice-switching therapy with splice-switching oligonucleotides (SSOs) has recently gained significant momentum for the treatment of various mis-splice disorders [1]
It is widely known that introduction of hydrophobic modifications into Cell-penetrating peptides (CPPs) can improve the ability of CPPs to formulate highly stable nanoparticles via non-covalent complexation with oligonucleotides
In the current study we took inspiration from the chemical approach used in peptide stapling by ruthenium-catalyzed ring-closing metathesis (RCM)
Summary
Splice-switching therapy with splice-switching oligonucleotides (SSOs) has recently gained significant momentum for the treatment of various mis-splice disorders [1]. Recent successful clinical trials for neuromuscular disorders, such as for Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), have demonstrated the excellent potential that SSO therapeutics can offer for the treatment of human disease. Despite these major breakthroughs, issues with the efficacy of SSO therapies persists and this is primarily attributed to the limited bioavailability of SSOs in the target tissues/cells. There is clearly enormous room for improving the delivery and efficacy of SSO-based therapeutic modalities
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.